Attenuation of reverse transcriptase facilitates SAMHD1 restriction of HIV-1 in cycling cells.
Cycling cells
HIV-1
Phosphorylation
Restriction
SAMHD1
dNTP levels
Journal
Retrovirology
ISSN: 1742-4690
Titre abrégé: Retrovirology
Pays: England
ID NLM: 101216893
Informations de publication
Date de publication:
01 05 2023
01 05 2023
Historique:
received:
24
02
2023
accepted:
06
04
2023
medline:
3
5
2023
pubmed:
2
5
2023
entrez:
1
5
2023
Statut:
epublish
Résumé
SAMHD1 is a deoxynucleotide triphosphohydrolase that restricts replication of HIV-1 in differentiated leucocytes. HIV-1 is not restricted in cycling cells and it has been proposed that this is due to phosphorylation of SAMHD1 at T592 in these cells inactivating the enzymatic activity. To distinguish between theories for how SAMHD1 restricts HIV-1 in differentiated but not cycling cells, we analysed the effects of substitutions at T592 on restriction and dNTP levels in both cycling and differentiated cells as well as tetramer stability and enzymatic activity in vitro. We first showed that HIV-1 restriction was not due to SAMHD1 nuclease activity. We then characterised a panel of SAMHD1 T592 mutants and divided them into three classes. We found that a subset of mutants lost their ability to restrict HIV-1 in differentiated cells which generally corresponded with a decrease in triphosphohydrolase activity and/or tetramer stability in vitro. Interestingly, no T592 mutants were able to restrict WT HIV-1 in cycling cells, despite not being regulated by phosphorylation and retaining their ability to hydrolyse dNTPs. Lowering dNTP levels by addition of hydroxyurea did not give rise to restriction. Compellingly however, HIV-1 RT mutants with reduced affinity for dNTPs were significantly restricted by wild-type and T592 mutant SAMHD1 in both cycling U937 cells and Jurkat T-cells. Restriction correlated with reverse transcription levels. Altogether, we found that the amino acid at residue 592 has a strong effect on tetramer formation and, although this is not a simple "on/off" switch, this does correlate with the ability of SAMHD1 to restrict HIV-1 replication in differentiated cells. However, preventing phosphorylation of SAMHD1 and/or lowering dNTP levels by adding hydroxyurea was not enough to restore restriction in cycling cells. Nonetheless, lowering the affinity of HIV-1 RT for dNTPs, showed that restriction is mediated by dNTP levels and we were able to observe for the first time that SAMHD1 is active and capable of inhibiting HIV-1 replication in cycling cells, if the affinity of RT for dNTPs is reduced. This suggests that the very high affinity of HIV-1 RT for dNTPs prevents HIV-1 restriction by SAMHD1 in cycling cells.
Sections du résumé
BACKGROUND
SAMHD1 is a deoxynucleotide triphosphohydrolase that restricts replication of HIV-1 in differentiated leucocytes. HIV-1 is not restricted in cycling cells and it has been proposed that this is due to phosphorylation of SAMHD1 at T592 in these cells inactivating the enzymatic activity. To distinguish between theories for how SAMHD1 restricts HIV-1 in differentiated but not cycling cells, we analysed the effects of substitutions at T592 on restriction and dNTP levels in both cycling and differentiated cells as well as tetramer stability and enzymatic activity in vitro.
RESULTS
We first showed that HIV-1 restriction was not due to SAMHD1 nuclease activity. We then characterised a panel of SAMHD1 T592 mutants and divided them into three classes. We found that a subset of mutants lost their ability to restrict HIV-1 in differentiated cells which generally corresponded with a decrease in triphosphohydrolase activity and/or tetramer stability in vitro. Interestingly, no T592 mutants were able to restrict WT HIV-1 in cycling cells, despite not being regulated by phosphorylation and retaining their ability to hydrolyse dNTPs. Lowering dNTP levels by addition of hydroxyurea did not give rise to restriction. Compellingly however, HIV-1 RT mutants with reduced affinity for dNTPs were significantly restricted by wild-type and T592 mutant SAMHD1 in both cycling U937 cells and Jurkat T-cells. Restriction correlated with reverse transcription levels.
CONCLUSIONS
Altogether, we found that the amino acid at residue 592 has a strong effect on tetramer formation and, although this is not a simple "on/off" switch, this does correlate with the ability of SAMHD1 to restrict HIV-1 replication in differentiated cells. However, preventing phosphorylation of SAMHD1 and/or lowering dNTP levels by adding hydroxyurea was not enough to restore restriction in cycling cells. Nonetheless, lowering the affinity of HIV-1 RT for dNTPs, showed that restriction is mediated by dNTP levels and we were able to observe for the first time that SAMHD1 is active and capable of inhibiting HIV-1 replication in cycling cells, if the affinity of RT for dNTPs is reduced. This suggests that the very high affinity of HIV-1 RT for dNTPs prevents HIV-1 restriction by SAMHD1 in cycling cells.
Identifiants
pubmed: 37127613
doi: 10.1186/s12977-023-00620-z
pii: 10.1186/s12977-023-00620-z
pmc: PMC10150492
doi:
Substances chimiques
RNA-Directed DNA Polymerase
EC 2.7.7.49
SAM Domain and HD Domain-Containing Protein 1
EC 3.1.5.-
Monomeric GTP-Binding Proteins
EC 3.6.5.2
SAMHD1 protein, human
EC 3.1.5.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5Subventions
Organisme : Wellcome Trust
ID : CC2056
Pays : United Kingdom
Organisme : Wellcome Trust
ID : CC2029
Pays : United Kingdom
Organisme : Medical Research Council
ID : CC2056
Pays : United Kingdom
Organisme : Medical Research Council
ID : CC2029
Pays : United Kingdom
Organisme : Cancer Research UK
ID : CC2056
Pays : United Kingdom
Organisme : Cancer Research UK
ID : CC2029
Pays : United Kingdom
Informations de copyright
© 2023. The Author(s).
Références
Hum Mutat. 2012 Jul;33(7):1116-22
pubmed: 22461318
Oncotarget. 2017 Jul 31;8(40):68517-68529
pubmed: 28978134
Nature. 2018 May;557(7703):57-61
pubmed: 29670289
Biochem Biophys Res Commun. 2016 Sep 2;477(4):977-981
pubmed: 27387229
Nature. 2011 May 25;474(7353):654-7
pubmed: 21613998
J Vis Exp. 2021 Jun 13;(172):
pubmed: 34180901
Trends Biochem Sci. 2003 Dec;28(12):625-8
pubmed: 14659692
Nucleic Acids Res. 2010 Apr;38(6):e85
pubmed: 20008099
Sci STKE. 2005 May 31;2005(286):re7
pubmed: 15928333
J Immunol. 2014 Aug 15;193(4):1988-97
pubmed: 25015816
Nat Med. 2014 Aug;20(8):936-41
pubmed: 25038827
J Biol Chem. 2004 Dec 3;279(49):51545-53
pubmed: 15452123
Virology. 2016 Aug;495:92-100
pubmed: 27183329
Virology. 2016 Jan 15;488:271-7
pubmed: 26655245
Biochemistry. 2021 Jun 1;60(21):1682-1698
pubmed: 33988981
Biochemistry. 1993 Nov 2;32(43):11569-74
pubmed: 8218224
Virology. 2013 Feb 5;436(1):81-90
pubmed: 23158101
Retrovirology. 2015 Jun 02;12:46
pubmed: 26032178
J Virol. 2018 Feb 26;92(6):
pubmed: 29321329
Autoimmunity. 2018 May;51(3):96-110
pubmed: 29583030
Antimicrob Agents Chemother. 2015 Jan;59(1):186-92
pubmed: 25331707
J Biol Chem. 2013 Mar 22;288(12):8101-8110
pubmed: 23364794
Virology. 1994 Apr;200(1):114-20
pubmed: 7510432
Sci Rep. 2016 Aug 11;6:31353
pubmed: 27511536
PLoS Pathog. 2011 Dec;7(12):e1002425
pubmed: 22174685
Retrovirology. 2012 Oct 23;9:87
pubmed: 23092122
Cell Rep. 2013 Apr 25;3(4):1036-43
pubmed: 23602554
Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):14272-7
pubmed: 23858451
Biochemistry. 2016 Nov 8;55(44):6087-6099
pubmed: 27775344
Cell Rep. 2017 Aug 22;20(8):1921-1935
pubmed: 28834754
Proc Natl Acad Sci U S A. 2020 Mar 10;117(10):5486-5493
pubmed: 32094182
J Leukoc Biol. 2015 Jul;98(1):5-14
pubmed: 25646359
Nucleic Acids Res. 2022 Jul 22;50(13):7545-7559
pubmed: 35801923
J Biol Chem. 2012 Jun 22;287(26):21570-4
pubmed: 22589553
Nat Commun. 2021 Jul 28;12(1):4582
pubmed: 34321470
Life Sci Alliance. 2019 Mar 27;2(2):
pubmed: 30918010
Nature. 2014 Jan 9;505(7482):234-8
pubmed: 24336198
J Biol Chem. 2015 Oct 30;290(44):26352-9
pubmed: 26294762
Nat Med. 2012 Nov;18(11):1682-7
pubmed: 22972397
Proc Natl Acad Sci U S A. 1981 Apr;78(4):2159-63
pubmed: 6264464
J Virol. 2014 May;88(10):5834-44
pubmed: 24623419
Retrovirology. 2013 Nov 12;10:131
pubmed: 24219908
PLoS Pathog. 2015 Oct 02;11(10):e1005194
pubmed: 26431200
Retrovirology. 2016 Aug 22;13(1):58
pubmed: 27549239
Nat Immunol. 2012 Feb 12;13(3):223-228
pubmed: 22327569
J Virol. 2014 Jun;88(12):7054-69
pubmed: 24672043
EMBO J. 2018 Jan 4;37(1):50-62
pubmed: 29084722
J Biol Chem. 2015 May 22;290(21):13279-92
pubmed: 25847232
Biochem Biophys Res Commun. 1992 Oct 30;188(2):879-87
pubmed: 1332707
J Virol. 2013 Nov;87(21):11516-24
pubmed: 23966382
Mol Cell. 2022 Oct 6;82(19):3712-3728.e10
pubmed: 36150385
J Biol Chem. 2012 Apr 6;287(15):12550-8
pubmed: 22362772
Nat Commun. 2020 Jun 23;11(1):3165
pubmed: 32576829
J Mol Med (Berl). 2013 Jun;91(6):759-70
pubmed: 23371319
Nucleic Acids Res. 2015 Jul 27;43(13):6486-99
pubmed: 26101257
Anal Biochem. 1989 Aug 1;180(2):222-6
pubmed: 2554751
Nat Commun. 2013;4:2722
pubmed: 24217394
Nat Struct Mol Biol. 2013 Nov;20(11):1304-9
pubmed: 24141705
Cancer Res. 1968 Aug;28(8):1559-65
pubmed: 4876978
Nature. 2011 Jun 29;474(7353):658-61
pubmed: 21720370
Nature. 2011 Nov 06;480(7377):379-82
pubmed: 22056990
J Biol Chem. 2011 Dec 23;286(51):43596-43600
pubmed: 22069334
Nat Commun. 2018 Jun 8;9(1):2227
pubmed: 29884836
Biochem Soc Trans. 2019 Aug 30;47(4):1013-1027
pubmed: 31296733
J Biol Chem. 2002 Jun 21;277(25):22662-9
pubmed: 11927582
Biochemistry. 2016 Oct 4;55(39):5635-5646
pubmed: 27588835
Cell Host Microbe. 2012 Feb 16;11(2):194-204
pubmed: 22284954
Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):E10022-E10031
pubmed: 30305425
Mob DNA. 2018 Mar 28;9:11
pubmed: 29610582
J Biol Chem. 2013 Apr 12;288(15):10406-17
pubmed: 23426366
Retrovirology. 2012 Jun 12;9:49
pubmed: 22691373
Cell Host Microbe. 2015 Apr 8;17(4):489-99
pubmed: 25856754